Amphastar Pharmaceuticals, Inc. Receives FDA Approval for Succinylcholine Chloride Injection USP, 200 mg/10 mL (20 mg/mL) Multiple-Dose VialGlobeNewsWire • 06/09/20
Amphastar Pharmaceuticals, Inc. (AMPH) Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/12/20
Why the Earnings Surprise Streak Could Continue for Amphastar (AMPH)Zacks Investment Research • 05/06/20
Amphastar Pharmaceuticals, Inc. Receives FDA Approval for Epinephrine Injection, USP 30mg/30mL (1mg/mL) Multiple Dose VialGlobeNewsWire • 04/27/20
Amphastar Pharmaceuticals, Inc. Announces Simplification of Management StructureGlobeNewsWire • 04/13/20
Amphastar Pharmaceuticals, Inc. (AMPH) Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 03/13/20
Amphastar Pharmaceuticals Receives FDA Approval for Supplement to its Abbreviated New Drug Application for Sodium Bicarbonate Injection, USP 8.4%, 50mEq/50mLGlobeNewsWire • 02/27/20
Amphastar Announces the Receipt of a MINOR CRL for Epinephrine Injection, USP 30mg/30mL (1mg/mL) Multiple Dose VialGlobeNewsWire • 01/28/20
Amphastar Pharmaceuticals, Inc. (AMPH) Management on Q3 2019 Results - Earnings Call TranscriptSeeking Alpha • 11/11/19
Amphastar Pharmaceuticals to Present at the Wells Fargo 2019 Healthcare ConferenceGlobeNewsWire • 08/29/19
Amphastar Pharmaceuticals, Inc. (AMPH) Q2 2019 Results - Earnings Call TranscriptSeeking Alpha • 08/11/19
Amphastar Pharmaceuticals (AMPH) Q1 Earnings and Revenues Surpass EstimatesZacks Investment Research • 05/09/19
This Biotech Sees Markets Worth Billions — But Can It Survive A 'Pause'?Investors Business Daily • 03/13/19